Jonathan Irish
-
Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine
A collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine. The group used multiple single-cell technologies, unbiased machine learning and traditional immunological approaches to track cellular and antibody responses in samples collected over time from a cohort of healthy participants. Read MoreJul 20, 2022
-
Discovery of aggressive cancer cell types by Vanderbilt researchers made possible with machine learning techniques
Rebecca Ihrie and Jonathan Irish are leading the development of machine learning applications for brain cancer research. Read MoreJun 24, 2020
-
Artificial intelligence offers a chance to optimize COVID-19 treatment in international partnership
Jonathan Irish joins an international collaboration by deploying artificial intelligence to optimize COVID-19 treatment and vaccine development. Read MoreMay 29, 2020
-
Deep Healing: Two alumni are making waves in drug discovery by plumbing the oceans’ depths for new therapeutic molecules
Sirenas, a San Diego-based company founded by Vanderbilt alumni Eduardo Esquenazi, BS'98, and Jake Beverage, BA'98, is applying trailblazing methods toward drug discovery. Read MoreSep 6, 2018
-
Looking beyond the ‘magic bullet’ approach to drug discovery
Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature. Read MoreMay 1, 2018
-
Investigators seek new way to define cell identity
Vanderbilt researchers hope their new method to describe cells will be widely adopted and used to generate a “Who’s Who” database of cell types. Read MoreMar 2, 2017
-
Single-cell analysis of solid tumors
A new method will make it possible to study solid tumors and healthy tissues using mass cytometry. Read MoreDec 12, 2016